Non-Alcoholic Steatohepatitis Treatment Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Non-Alcoholic Steatohepatitis Treatment Market Growth From $4.98 Billion In 2026 To $18.97 Billion By 2030 At A CAGR Of 39.7%
The market for non-alcoholic steatohepatitis treatments has seen explosive expansion in recent years. Valued at $3.57 billion in 2025, it is projected to reach $4.98 billion by 2026, reflecting a compound annual growth rate (CAGR) of 39.6%. This historic growth has been driven by factors such as the growing prevalence of obesity, a rising number of type 2 diabetes cases, high intake of processed foods, insufficient awareness regarding liver health, and a scarcity of therapeutic options for early-stage NASH.
The non-alcoholic steatohepatitis treatment market is projected to experience substantial expansion in the coming years, with its value anticipated to reach $18.97 billion by 2030, representing a compound annual growth rate (CAGR) of 39.7%. This upward trajectory during the forecast period is largely driven by progress in precision medicine, the creation of innovative NASH therapies, the integration of digital health monitoring technologies, governmental efforts aimed at preventing liver disease, and heightened funding for liver disease research. Key developments shaping this period include a focus on tailored lifestyle and dietary plans, progress in non-invasive diagnostic techniques, initiatives to raise awareness about fatty liver disease, at-home liver health monitoring solutions, and the emergence of new pharmacological agents.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Alcoholic Steatohepatitis Treatment Market Demand Drivers Creating New Revenue Opportunities
The rising prevalence of insulin resistance is a key driver behind the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance is a condition where muscle, fat, and liver cells fail to respond appropriately to insulin, making it difficult for the body to absorb glucose from the bloodstream and often resulting in elevated blood sugar levels. This condition is frequently linked to factors such as poor lifestyle choices, excessive sugar intake, and genetic predisposition. Due to the growing incidence of diabetes and other liver-related disorders, the use of non-alcoholic steatohepatitis treatments has increased substantially to manage insulin resistance. For example, data from PubMed—a free biomedical literature database managed by the U.S. National Library of Medicine—released in July 2025 showed notable rises in the prevalence of general obesity (from 34.9% to 41.4%), abdominal obesity (from 62.5% to 67.0%), severe obesity (from 5.2% to 11.5%), and insulin resistance (from 22.5% to 30.2%). As a result, the growing frequency of insulin resistance, driven by rising rates of liver diseases and diabetes, is expected to propel the non-alcoholic steatohepatitis treatment market forward.
Non-Alcoholic Steatohepatitis Treatment Market Segment Performance And Strategic Opportunities
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Non-Alcoholic Steatohepatitis Treatment Market Trends Driving Strategic Industry Expansion
Key players in the non-alcoholic steatohepatitis treatment market are focusing on the creation of advanced solutions like endogenous hormones to attract a broader customer base, boost sales, and drive revenue growth. Endogenous hormones are naturally produced within the body by various glands, tissues, or organs and are essential for regulating physiological functions. For example, in September 2023, 89bio Inc., a biotechnology firm based in the United States, revealed that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation (BTD) to Pegozafermin for patients with nonalcoholic steatohepatitis (NASH). Pegozafermin is a unique product, distinguished by its engineered glycoPEGylated analog of fibroblast growth factor 21. This specially designed formulation is being developed to treat non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Its distinctiveness lies in the application of a specialized glycoPEGylated technology, which provides an extended half-life while maintaining its effectiveness. This innovative method improves the product’s ability to influence critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, such as reducing triglycerides, controlling blood sugar, and addressing steatosis, inflammation, and fibrosis.
Non-Alcoholic Steatohepatitis Treatment Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Access The Complete Non-Alcoholic Steatohepatitis Treatment Market Report:
Non-Alcoholic Steatohepatitis Treatment Market Largest Region By Revenue And Market Share
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
